Rejuvenate Bio is a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases. Rejuvenate Bio has built a gene therapy pipeline with huge potential in chronic disease by utilizing clinically validated gene targets and a delivery approach that ensures well tolerated, durable expression. Founded on scientific research developed at the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed groundbreaking therapies to treat chronic age-related disease in both humans and animals.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
06/08/26	$6,000,000		Connecticut Innovations Digitalis Ventures Kendall Capital Partners Merck Animal Health VCapital	undisclosed